BioNote, Inc. (KRX:377740)
South Korea · Delayed Price · Currency is KRW 5,570.00
+70.00 (1.27%)
At close: Nov 26, 2025
BioNote Revenue
BioNote had revenue of 29.50B KRW in the quarter ending September 30, 2025, with 11.53% growth. This brings the company's revenue in the last twelve months to 115.09B, up 15.32% year-over-year. In the year 2024, BioNote had annual revenue of 102.78B with 14.10% growth.
Revenue (ttm)
115.09B
Revenue Growth
+15.32%
P/S Ratio
4.91
Revenue / Employee
386.22M
Employees
298
Market Cap
564.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 102.78B | 12.70B | 14.10% |
| Dec 31, 2023 | 90.08B | -389.58B | -81.22% |
| Dec 31, 2022 | 479.66B | -142.70B | -22.93% |
| Dec 31, 2021 | 622.36B | -9.15B | -1.45% |
| Dec 31, 2020 | 631.50B | 591.46B | 1,476.89% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |